YESAFILI

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Lithuania, United States

Active ingredients

The drug YESAFILI contains one active pharmaceutical ingredient (API):

1 Aflibercept UNII 15C2VL427D - AFLIBERCEPT

Aflibercept, also known as VEGF TRAP in the scientific literature, is a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of the human IgG1. Aflibercept blocks the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients. Read about Aflibercept

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
YESAFILI Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01LA05	Aflibercept	S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3045978
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097802, 1097803
Country: US	FDA, National Drug Code	Identifier(s): 83257-013